- Differences in major adverse cardiovascular events of metabolic dysfunction-associated steatotic liver disease by race and ethnicity: Letter to the editor on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”
-
Chang HC, Liao WC, Fang YJ, Chen SJ, Gau SY
- KMID: 2560101
- Clin Mol Hepatol.
- 2024 Oct;30(4):978-981.
- doi: 10.3350/cmh.2024.0565
-
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation
-
Tsai YN, Wu JL, Tseng CH, Chen TH, Wu YL, Chen CC, Fang YJ, Yang TH, Nguyen MH, Lin JT, Hsu YC
- KMID: 2549386
- Clin Mol Hepatol.
- 2024 Jan;30(1):98-108.
- doi: 10.3350/cmh.2023.0194
Background/Aims: Finite nucleos(t)ide analog (NA) therapy has been proposed as an alternative treatment strategy for chronic hepatitis B (CHB), but biomarkers for post-treatment monitoring are limited. We investigated whether measuring... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study
-
Chang CW, Wei SC, Chou JW, Hsu TC, Chuang CH, Lin CP, Hsu WH, Yen HH, Lin JK, Fang YJ, Wang HY, Lin HH, Wu DC, Ni YH, Wang CY, Wong JM
- KMID: 2174405
- Intest Res.
- 2014 Oct;12(4):287-292.
- doi: 10.5217/ir.2014.12.4.287
BACKGROUND/AIMS: Only moderate to severe Crohn's Disease (CD) patients without a satisfactory conventional therapy effect are eligible to get reimbursement from the National Health Insurance of Taiwan for using adalimumab.... -
- CITED
-
- Close
- SHARE
-
- Close
- Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
-
Liu CH, Chen CY, Su WW, Liu CJ, Lo CC, Huang KJ, Chen JJ, Tseng KC, Chang CY, Peng CY, Shih YL, Huang CS, Kao WY, Yang SS, Tsai MC, Wu JH, Chen PY, Su PY, Hwang JJ, Fang YJ, Lee PL, Tseng CW, Lee FJ, Lai HC, Hsieh TY, Chang CC, Chang CH, Huang YJ, Kao JH
- KMID: 2520841
- Clin Mol Hepatol.
- 2021 Oct;27(4):575-588.
- doi: 10.3350/cmh.2021.0155
Background/Aims: Real-world studies assessing the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) plus ribavirin (RBV) for Child-Pugh B/C hepatitis C virus (HCV)-related cirrhosis are limited. Methods: We included 107 patients with Child-Pugh... -
- CITED
-
- Close
- SHARE
-
- Close
